Our experts develop in vitro assays in a high-throughput format to support projects throughout the drug discovery process. Cell-based assays and biochemical assays in 384-well and 1536-well plates are developed to be used in HTS campaigns and to provide data during hit-to-lead and lead optimization, facilitating preclinical advancement to in vitro and in vivo.
Our technology platforms support multiple readouts such as fluorescence intensity (including FRET), luminescence (including BRET), absorbance, fluorescence polarization, AlphaScreen, time-resolved fluorescence, immunofluorescence, and qPCR. We have developed assays across target classes including GPCRs, receptor tyrosine kinases, multiple enzyme classes, protein-protein interactions, and gene expression.
In addition, we have extensive experience in Infectious Disease drug discovery including screening within BSL-3 containment; our assay development includes bringing new virus variants online to ensure the highest relevance of your results. Our assays are compatible with small molecules and biologics and the readouts include cytopathic effect, reporter virus, immunofluorescence, and AlphaScreen. Our overall goal is to produce results that accurately reflect the biology being studied with the throughput to quickly inform your critical decisions.
